Philadelphia Priest Dies After Participating In Moderna COVID Vaccine Trial

As mil­lions of elder­ly Amer­i­cans pre­pare to take COVID-19 vac­cines that, accord­ing to numer­ous reports, can elic­it some pret­ty seri­ous post-2nd dose side-effects for a day or so, Life­Site­News has report­ed that a Ukrain­ian Greek-Catholic priest died at his PA home after par­tic­i­pat­ing in Mod­er­na’s vac­cine trial.

The cause of death isn’t yet known, and it’s unclear whether his par­tic­i­pa­tion in the tri­al for the new mRNA vac­cine is con­nect­ed to the death.

Father John Fields was the Com­mu­ni­ca­tions and Reli­gious Edu­ca­tion Direc­tor for the Archep­archy of Philadel­phia, which is part of the Ukrain­ian Greek-Catholic Church. In the announce­ment of his death, the Archep­archy stat­ed that Father Fields “has passed away in his home. The cause of death is yet to be deter­mined”. The priest was 70.

JFields recent­ly par­tic­i­pat­ed in the tri­als of Moderna’s COVID-19 vac­cine after receiv­ing an email from the Uni­ver­si­ty of Penn­syl­va­nia at the end of August ask­ing if he wished to “par­tic­i­pate in the third and final phase” of the vac­cine trial.

He was report­ed­ly approached because of his age, since he was in the age brack­et the study team “deemed the high­er risk group for the COVID-19 virus.” The first injec­tion he received was on Aug. 31, with the sec­ond on Oct. 1.

Notably, the priest report­ed no seri­ous symp­toms after the sec­ond dose.

“I think of the researchers, who in only sev­er­al months, as part of Oper­a­tion Warp Speed, col­lec­tive­ly used their knowl­edge and wis­dom from Almighty God to achieve this med­ical mile­stone,” he had said. “I may be able [to] con­tribute in some small way to the devel­op­ment of an effec­tive vac­cine that would help stop this world­wide COVID-19 pan­dem­ic and the fear.”

Before jump­ing to con­clu­sions, it’s worth not­ing that anoth­er priest sug­gest­ed that Father Fields might have had a heart attack. But some orga­ni­za­tions have raised ques­tions about the rate of “seri­ous” injury in the high-risk group of Mod­er­na tri­al vol­un­teers, as was dis­closed with the lat­est round of ‘Phase 3’ tri­al data.

Three of the 15 human guinea pigs in the high-dose cohort — 250MG — report­ed­ly suf­fered a “seri­ous adverse event” with­in 43 days of receiv­ing Mod­er­na’s jab.

Full Sto­ry

NEVER MISS OUT! Join our popular newsletter


Big Tech is at war with you! They don't want you to see the truth.



. . .
Send this to a friend